Cell line · CVCL_4782
Papers60
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 60
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Obesity-Induced PLPE-PTK6-FASN Feedback Loop Drives Enzalutamide Resistance by Exacerbating Lipid Metabolic Dysregulation in Castration-Resistant Prostate Cancer. | Research (Wash D C) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Prostate Cancer Patient-Derived Organoids (PDOs) as Functional Avatars for Antisense Oligonucleotide (ASO)-Based Personalized Therapy. | Adv Healthc Mater | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Castration-resistant prostate cancer cells are addicted to the high activity of cyclin-dependent kinase 2. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SLPI is associated with AR-regulated epithelial adaptation and enzalutamide sensitivity in castration-resistant prostate cancer. | Front Pharmacol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Vitronectin Enrichment in Prostate Cancer Liver Metastases Promotes Adhesion and Survival. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The YAP1-NPM1 nuclear complex regulates MYC and reveals a targetable oncogenic node. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer. | J Clin Invest | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage. | J Cell Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lactate derived from cancer-associated fibroblasts promotes alternative splicing and castration resistance in prostate cancer. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The YAP1 and EPHA3 receptor tyrosine kinase axis regulates cellular plasticity and treatment response. | Cell Signal | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Synthesis of Bispecific Conjugates by ADP-Ribosyl Cyclases. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical Activity of the DLL3-Targeted T-cell Engager MK-6070 in Neuroendocrine Prostate Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Synergistic Efficacy of Gedatolisib and Darolutamide in Prostate Cancer to Overcome Resistance to Androgen-Targeted Therapy. | Int J Mol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| KBTBD11 loss promotes AKT hyperactivation and therapeutic vulnerability in prostate cancer. | Oncogene | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A bioinformatics screen identifies TCF19 as an aggressiveness-sustaining gene in prostate cancer. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Extracellular Domain Shedding of TROP2 Activates EGFR Signaling to Drive Prostate Cancer Metastasis. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_4782/papers